Clinical Trial

A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 8, 2025 (before its estimated August 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the efficacy and safety of induction Adebrelimab (anti-PD-L1 antibody) combined with chemotherapy, then guided by PET-CT or RECIST1.1 assessment to change the following chemoradiotherapy regiment for locally advanced unresectable ESCC.
Trial Details
NCT Number NCT07112833
Lead Sponsor Hebei Medical University Fourth Hospital
Conditions Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Enrollment 36 participants
Start Date 2025-08-10
Primary Completion 2025-08-10 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-08